Patent intelligence · CA
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
Patent details — CA 3259391
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Feb 1, 2024
- Expiration
- Jan 27, 2044
- Applicant
- ABBVIE BIOTHERAPEUTICS INC [US]
- CPC classes
- A61K 39/ 00 A I, A61K 39/ 395 A I, A61K/31282, A61K/31337
Quick answer
CA 3259391 (POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1) is held by ABBVIE BIOTHERAPEUTICS INC [US]. Status: granted. Granted Feb 1, 2024. Expires Jan 27, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE BIOTHERAPEUTICS INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 00 A I, A61K 39/ 395 A I, A61K/31282, A61K/31337, A61K/31519, A61K/317068
More from ABBVIE BIOTHERAPEUTICS INC [US]
Related pharmaceutical patents in our USPTO index.
-
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
granted -
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
CA 3245150
COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE
granted -
US 2023174645
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
granted -
CA 3235096
METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted
Frequently asked questions
What is US patent 3259391?
CA 3259391 (POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1) is held by ABBVIE BIOTHERAPEUTICS INC [US]. Status: granted. Granted Feb 1, 2024. Expires Jan 27, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3259391?
ABBVIE BIOTHERAPEUTICS INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does CA 3259391 expire?
Our index shows an expiration date of Jan 27, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.